PurMinds NeuroPharma Inc.

12:45 PM - 1:00 PM (PDT), Monday, June 13, 2022
PurMinds is an innovative precision NeuroMedicine company pursuing breakthrough solutions to neurodegenerative diseases by progressing a robust clinical pipeline derived from multi-omics studies and an AI and data driven drug discovery platform.

PurMinds drug development pipeline includes small molecule, psychedelic and other therapeutic candidates. Our near- and medium-term milestones include multiple pre-clinical studies, clinical trials and patent filings targeting diseases such as ALS, Alzheimer’s and Frontotemporal Dementia, etc.

PurMinds' PurPrecision NeuroMedicine Discovery Platform is powered by leading-edge neuronal screening technologies, multi-omics studies, big data and machine learning engines. It can generate unique molecular signatures of the diseases and novel therapeutic targets that directly inform and continuously refine and de-risk our pipeline.

PurMinds owns a neurolab with Health Canada approved license for Controlled Substances (Narcotics & psychedelic
Company Type:
Privately Funded Company
Company HQ State:
Ontario
Company HQ Country:
Canada
Year Founded:
2018
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
PurOG-1 for ALS and FTD
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
6
Speaker
photo
Chief Scientific Officer
PurMinds NeuroPharma Inc.